Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival.
Sign Up to like & getrecommendations! Published in 2019 at "Future oncology"
DOI: 10.2217/fon-2018-0659
Abstract: Approximately 50% of cutaneous melanomas harbor activating mutations of the BRAF-oncogene, making BRAF inhibitors (BRAFi) the standard treatment for this disease. However, disease responses are limited in duration mainly due to acquired resistance. Dual MAPK pathway… read more here.
Keywords: long term; melanoma mek; malignant melanoma; cobimetinib malignant ... See more keywords